GSK'547 is a highly selective and potent inhibitor of RIP1 (RIPK1) with a 400-fold increase in oral exposure compared to GSK'963 in mouse pharmacokinetic studies.

 

Brand: BCM

 

Target: RIP kinase

 

Signaling Pathways: Apoptosis; NF-κB

 

In Vitro: In vitro, treatment with GSK'547 directed the development of an immunogenic phenotype in bone marroe-derived macrophages, upregulating the expression of MHC-II, TNFa, and IFNg, while decreasing the expression of CD206, IL-10, and TGFb. In addition, GSK'547 upregulated STAT1 signaling and decreased STAT3, STAT5, and STAT6 signaling in bone marrow-derived macrophages. Macrophages treated with GSK'547 have a greater ability to capture antigens.

 

Boiling Point: 578.3±60.0 °C(Predicted)

 

pKa: 1.93±0.28(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; Insoluble in Ethanol.

 

GHS: GHS07

 

Isomeric SMILES: C1CN(CCC1C(=O)N2[C@@H](CC=N2)C3=CC(=CC(=C3)F)F)C4=NC=NC(=C4)C#N  

 

InChIKey: SJVGFKBLUYAEOK-SFHVURJKSA-N  

 

InChI: InChI=1S/C20H18F2N6O/c21-15-7-14(8-16(22)9-15)18-1-4-26-28(18)20(29)13-2-5-27(6-3-13)19-10-17(11-23)24-12-25-19/h4,7-10,12-13,18H,1-3,5-6H2/t18-/m0/s1

 

Attribute
[CAS No.]	2226735-55-1
[Formula]	C20H18F2N6O
[Molecular]	396.4
[Chem Name]	6-[4-[(3S)-3-(3,5-difluorophenyl)-3,4-dihydropyrazole-2-carbonyl]piperidin-1-yl]pyrimidine-4-carbonitrile
[Storage]	Inert atmosphere. Room Temperature
[Synonym]	CPD3508; GSK547
[MDL No.]	MFCD32062767
[Form]	Solid Powder

Goods Tag